QCR Global Group
QCR Global Group, formerly known as QCR Global Group, is a think tank company dedicated to health equality and bridging the gap in healthcare access worldwide. They focus on addressing disparities influenced by social, economic, and environmental factors, aiming to extend cost-effective health solutions globally. Their mission involves active participation in promoting health equity across 18 targeted countries, impacting over 254,000 families through collaborations with health organizations and the life sciences industry. They also focus on innovative opportunities such as digital and AI health solutions to help children living in poverty and improve access to orphan drugs in emerging markets.
Industries
Nr. of Employees
small (1-50)
QCR Global Group
New York, New York, United States, North America
Products
Analytical reports on health equity and market access
Published articles and reports examining health disparities, cost impacts, and regulatory pathways for rare disease therapies in emerging markets.
Analytical reports on health equity and market access
Published articles and reports examining health disparities, cost impacts, and regulatory pathways for rare disease therapies in emerging markets.
Services
Research and advisory services on health equity, regulatory pathways, and policy interventions for governments, NGOs, and industry.
Design and coordination of multi-country health equity initiatives and facilitation of collaborations between health organisations and industry partners.
Preparation and publication of articles, whitepapers, and explanatory content on orphan drug access, health disparities, and related policy topics.
Research and advisory services on health equity, regulatory pathways, and policy interventions for governments, NGOs, and industry.
Design and coordination of multi-country health equity initiatives and facilitation of collaborations between health organisations and industry partners.
Preparation and publication of articles, whitepapers, and explanatory content on orphan drug access, health disparities, and related policy topics.
Expertise Areas
- Health equity policy
- Regulatory strategy for orphan drugs
- Global health program implementation
- Digital health strategy
Key Technologies
- AI and digital health platforms
- Data analytics for population health
- Regulatory pathway mapping and analysis tools
News & Updates
An article discussing the legislative policies in the US and EU that expedite review and approval of orphan drugs, and the challenges faced by emerging and frontier countries in adopting similar regulations.
Addressing disparities in health status and quality of care, leading to a $93 billion loss in medical costs, and promoting policies for health equality.
An article discussing the legislative policies in the US and EU that expedite review and approval of orphan drugs, and the challenges faced by emerging and frontier countries in adopting similar regulations.
Addressing disparities in health status and quality of care, leading to a $93 billion loss in medical costs, and promoting policies for health equality.